[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418061":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":24,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":24,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":24,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":24,"overallStatus":33,"whyStopped":24,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing\u002Ftiming of indocyanine green has not been fully studied will be enrolled: glioma, breast cancer, colon cancer, rectal cancer, head and neck cancer, pulmonary metastasectomy (colorectal mets), thymoma, ovarian cancer, prostate cancer, renal cell carcinoma, thyroid cancer, parathyroid adenoma, mesothelioma, esophageal cancer, pancreas cancer, stomach cancer.",[13],"Drug: Indocyanine Green",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing\u002Ftiming of indocyanine green has been fully studied will be enrolled: non-small cell lung cancer, metastatic sarcoma to the lung, brain meningioma.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Indocyanine Green","The investigational drug is indocyanine green, single dose between 1-5 mg\u002Fkg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Azra Din","CONTACT","215-615-7980","azra.din@pennmedicine.upenn.edu",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-75.16362,39.95238,{"lat":43,"lon":42},[46,48],{"name":47,"role":28,"phone":29,"phoneExt":24,"email":30},"Azra Din, MPH",{"name":24,"role":28,"phone":24,"phoneExt":24,"email":30},{"type":50,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100418061","phase-1-tumorglow-intraoperative-molecular-imaging-imi-100418061",false,"NCT04723810","TumorGlow Intraoperative Molecular Imaging (IMI)","A Study to Evaluate the Safety and Efficacy of Indocyanine Green for Intraoperative Molecular Imaging of Solid Tumors (TumorGlow™)","Inclusion Criteria:\n\n* Adult patients 18 years of age or older.\n* Patients presenting with any solid tumor and\u002For diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment.\n* Good operative candidate as determined by the treating physician and\u002For multidisciplinary team.\n* Subject capable of giving informed consent.\n\nExclusion Criteria:\n\n* Subject unable to participate in the consent process.\n* Vulnerable population including pregnant women, prisoners, and children.\n* History of uncontrolled hypertension (e.g., history of an ER admission for hypertensive crisis or ≥ 3 blood pressure medications)\n* Patients with a self-reported history of iodide allergies.","ALL","18 Years",{"count":61,"type":62},500,"ESTIMATED","INTERVENTIONAL",[65,66],"PHASE1","PHASE2","This is a Phase 1\u002F2 study in patients presenting with any solid tumor and\u002For diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.",[69],"Tumor, Solid","2026-03-05",{"date":72,"type":73},"2026-03-09","ACTUAL",{"date":75,"type":73},"2024-08-14",{"date":77,"type":62},"2027-01-14",{"name":5,"class":6},1]